December 1, 2017

**Announcements**

**ESAB Site Visit Today**
The leadership of Yale Cancer Center welcomes our External Scientific Advisory Board to campus today for our annual site visit. Chaired by Robert Diasio, MD, Director of the Mayo Clinic Cancer Center, the 20 member advisory board will hear presentations from our research programs and other sections of our Cancer Center Support Grant in preparation for our upcoming site visit from the NCI Review Committee on January 25, 2018. Thank you to our entire leadership team for their tireless efforts in preparation for today's meeting.

**SABCS and ASH Participation**
Over the next week, members of our Breast Center and Hematology teams will travel to the San Antonio Breast Cancer Symposium and to the American Society of Hematology annual meeting to present research and clinical advances from Yale Cancer Center and Smilow Cancer Hospital. Several faculty members have presentations on the podium and poster presentations. If you are attending either meeting, please take the time to support your colleagues during their presentations.

SABCS Presentations >>
ASH Annual Meeting Presentations >>

**Pancreatic Cancer CME Symposium**
Please reserve Friday, February 2 for a CME Symposium on the Multidisciplinary Management of Pancreatic Cancer at Yale’s West Campus. A full agenda will be available in the coming weeks, as well as registration information.

Learn More >>
Notables

The American Cancer Society received a three-year grant totaling $327,000 from The Community Foundation for Greater New Haven's Edith P. Rausch Fund to fund two Postdoctoral Fellowship Pay-If grants at Yale. Cai Roberts, PhD, in the department of Obstetrics, Gynecology & Reproductive Sciences will investigate the "Crosstalk Between p53 and TWIST in Chemoresistant Ovarian Cancer." James Brewer, PhD in the laboratory of Dr. Richard Flavell, will lead the second project, "Investigating Nuclear Inflamasome Effector Functions."

Roy S. Herbst, MD, PhD, received a place on the Wall of Fame during a ceremony earlier this week at his alma mater, New Rochelle High School in NY.

Employee Profile: Samantha Herlihy
After joining Yale New Haven Health in July 2015 as a Clinical Nurse 2, Samantha Herlihy knew working on the oncology floors at Smilow was meant to be. As an undergraduate at UConn, she planned to work as a psychiatric nurse upon graduation because she enjoyed the psycho-social needs of that patient population. However, after completing her senior year capstone project on a general oncology floor, she changed course and decided to shift her focus to oncologic nursing.

Samantha found it was the perfect balance of medical and psychiatric nursing, and when she joined Smilow full time, she started on the 14th floor working with mostly gyn-onc post-operative patients. The experience initially was much different than nursing school, but she was bolstered by the support of her colleagues and a wonderful preceptor, and quickly adjusted.

Samantha’s transition into her full-time role was also bolstered by the strength of the patients she saw each day. On NP 14, she cared for mostly female patients who were coping with breast, ovarian, and cervical cancers, and she was moved by their eye-opening strength. Two years later in the fall of 2017, Samantha transferred to NP 15 to increase her experience in acute care. This move has given Samantha the opportunity to flourish. She is an active member of the Nursing Research Committee at YNHH and was ecstatic to have the opportunity to travel to the Oncology Nursing Society (ONS) conference in Denver, Colorado and present a poster on ‘Coping Strategies for Staff Caring for Actively Dying Patients: Implementation of Guided Imagery and Staff Perception of Compassion Fatigue.’

In just two and a half years at Smilow, Samantha has been able to grow and spread her wings thanks to the support of her colleagues and preceptors.
and encouragement of her peers and managers. "I am very proud to work at Smilow Cancer Hospital and I'm proud of my coworkers and friends," she notes. "The teamwork - especially within a big organization, has been incredible."

"Having the patient relationships and supportive coworkers, it has been a wonderful experience for me; I learn something new every day."

#OOTBTHANKS

#OOTB: Courtney Frederick

YCC #OUTOFTHEBLUETHANKS recently recognized Courtney Frederick, RN, Licensed Clinical Research Coordinator for the Breast Team in the Clinical Trials Office. In recent months, Courtney has joined a completely new team with which she has shared her experiences and knowledge while also welcoming their new ideas. Courtney's commitment to the study participants, the team, and to the advancement in breast oncology treatment makes her a truly special addition to the Clinical Trials Office and one that sets an excellent example for all of us. Thank you, Courtney!

Yale Cancer Center's #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. All nominations should be submitted to the Director's Office c/o Anna Raso.

Funding Opportunities

Lion Heart Fund for Cancer Research

As Lung Cancer Awareness Month draws to a close, we continue to highlight the strength of our patient survivors. Today, meet Maureen, a patient who received a diagnosis of stage IV lung cancer but was determined to put up a fight. This resolve paid off: with the guidance of her oncologist, she was one of the first patients in the nation to join a clinical trial at Smilow using immunotherapy, and a year later, all of her tumors had started to shrink. She paved the way for so many other patients!

Welcome, Dr. Heather Osborn! Dr. Osborn recently joined as an Assistant Professor in the Section of Otolaryngology, coming from a clinical fellowship at Harvard Medical School. We are especially excited about the skill and experience she brings to the Head & Neck Cancers Program at Smilow!

Today, we are thankful for our physicians, nurses, and caregivers who tirelessly care for our patients every
Yale investigators are encouraged to submit proposals of innovative, high-potential projects requiring pilot funding. Projects may be in any area of breast cancer research - basic, translational, clinical, outcomes and population science are all welcomed from any discipline or group of disciplines.

Proposal Due Date: December 4, 2017
Learn More >>

Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers.

Letter of Intent Deadline: December 5, 2017
Learn More >>

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. This Funding Opportunity Announcement (FOA) invites U01 application for projects aimed at identifying best practices to improve case ascertainment of hereditary cancers, with the goal of improving prevention and detection.

Letter of Intent Deadline: December 9, 2017
Read More >>

Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy.

Application Deadline: December 14, 2017
Read More >>

This afternoon's rain left a beautiful scene over the healing garden on the seventh floor of Smilow Cancer Hospital.
**2018 Catalyst Grant**

Supports a junior faculty to conduct pancreatic cancer research and establish successful career paths in the field with a $500,000 grant over three years. Proposed research may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.

**Application Deadline:** December 15, 2017

---

**Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24)**

The purpose of this specific FOA is to establish a Data Resource associated with clinical trials in cellular immunotherapy as a component of the Immuno-Oncology Translation Network (IOTN).

**Letter of Intent and Application Deadlines:**

December 16, 2017; January 16, 2018

---

**Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (DMRC) (U24)**

The purpose of this FOA is to establish a Data Management and Resource-sharing Center to provide overall support for the Immuno-Oncology Translational Network (IOTN) and to integrate the research activities of the IOTN with other Cancer Moonshot Initiative programs.

**Letter of Intent and Application Deadlines:**

December 16, 2017; January 16, 2018

---

**Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01)**

The purpose of this specific FOA is to establish Cancer Immunoprevention Research Projects that will function as components of a Cancer Immunotherapy Consortium (CIC), which will also include Cancer Immunotherapy Research Projects.

**Letter of Intent and Application Deadlines:**

December 16, 2017, January 16, 2018
The purpose of this FOA is to establish a Cancer Immunotherapy Consortium (CIC) composed of organ site-specific Cancer Immunotherapy Research Projects as a component of the Immuno-Oncology Translation Network (IOTN).

**Letter of Intent and Application Deadlines:**
December 16, 2017; January 16, 2018
[Learn More >>](#)

**Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01)**
Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP):
Accelerate research that can identify approaches to monitor and manage patient-reported symptoms.

**Letter of Intent and Application Deadlines:**
December 17, 2017; January 17, 2018
[Learn More >>](#)

**Coordinating Center for Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (U24)**
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory.

**Letter of Intent and Application Deadlines:**
December 17, 2017; January 17, 2018
[Learn More >>](#)

**Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (UM1)**
This FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory.

**Letter of Intent and Application Deadlines:**
December 17, 2017; January 17, 2018
[Learn More >>](#)

**Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS): Coordinating Center (U24)**
The purpose of this FOA is to promote research in...
colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

**Letter of Intent and Application Deadlines:**
December 18, 2017; January 18, 2018

Learn More >>

**Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS) (UG3/UH3)**
The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

**Letter of Intent and Application Deadlines:**
December 18, 2017; January 18, 2018

Learn More >>

**Human Tumor Atlas Network: Data Coordinating Center (U24)**
The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

**Letter of Intent and Application Deadlines:**
December 18, 2017; January 18, 2018

Learn More >>

**Pre-Cancer Atlas (PCA) Research Centers (U2C)**
The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases. For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors.
Letter of Intent and Application Deadlines:
December 18, 2017; January 18, 2018
Learn More >>

Human Tumor Atlas Research Centers (U2C)
The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem.
Letter of Intent and Application Deadlines:
December 18, 2017; January 18, 2018
Learn More >>

Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)
This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem.
Application Due Date: January 8, 2018
Learn More >>

The Howard Hughes Medical Institute - The Hanna H. Gray Fellows Program Competition
The goal of the Hanna H. Gray Fellows Program is to recruit and retain individuals who are from gender, racial, ethnic, and other groups underrepresented in the life sciences, including those from disadvantaged backgrounds, early in their careers.
Application Deadline: January 10, 2018
Learn More >>

2018 Translational Research Grant
Supports independent investigators conducting high priority pancreatic cancer research that is poised for important translational next steps with a $500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.
Application Deadline: January 15, 2018
Learn More >>

Pathology Special Seminar
TAC N-107
Lineage Transcription Factors as Determinants of Lung Cancer Heterogeneity and Metastasis
Anna Arnal Estate
Read More >>

December 5; 11:30AM
Department of Genetics Seminar Program
TAC N-107
Mutation and Selection in Cancer
Shamil Sunyaev, PhD
Read More >>

December 5; 12:00PM
Yale Cancer Center Grand Rounds
Park Street Auditorium
Skin Cancer in Solid Organ Transplant Recipients
Oscar Colegio, MD, PhD
AJCC Cancer Staging Manual: Overview of Chapter 1 Staging Rules
Teresita Vega, BA
Read More >>

December 5; 4:00PM
Human and Translational Immunology Seminars
TAC N-203
Molecular Determinants of T Cell Phenotypes in Cancer
Ana Anderson, PhD
Read More >>

December 5; 5:00PM
Yale Liver Center Seminar Series
TAC S-247
Identifying New Molecular Targets to Reduce Inflammation and Learning on Their Role in Tissue Dysfunction of Chronic Diseases
Juan Carlos Saez, PhD
Read More >>

December 6; 8:00AM
Rheumatology Grand Rounds
TAC N-203
Exosome Intercellular Epigenetic RNA Transfers: New Players in Immunology
Read More >>
methods for preclinical testing of single agents and drug combinations; and c) Conducting response studies of PDX models, primarily from racially/ethnically diverse populations, to develop novel therapeutic strategies.

**Application Due Date:** January 18, 2018

Learn More >>

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)
The goals for this FOA include the development of translational research programs focused upon investigating cancer health disparities.

**Application Due Date:** January 18, 2018

Learn More >>

Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers.

**Application Due Date:** January 29, 2018

Learn More >>

Recent Publications

**Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.**

Read More >>

**RNA-seq Based Transcription Characterization of Fusion Breakpoints as a Potential Estimator for Its Oncogenic Potential.**

Read More >>

and Inflammation
Philip W. Askenase, MD
Read More >>

December 6; 2:00PM
Department of Pharmacology Presents the 2017 Alan C. Sartorelli Lecture on Cancer Research
Brady Auditorium B131
Translational Control of Cancer by eIF4E via the mTOR and MAPK Pathways
Nahum Sonenberg, PhD
Read More >>

December 7; 10:30AM
Immunobiology Seminar Series
TAC N-107
Complexity of Intestinal Macrophages in Health and Disease
Milena Bogunovic, MD, PhD
Read More >>

December 7; 12:00PM
Yale Cancer Center Special Seminar
FMB 115
Challenges and Opportunities in Glioma Therapeutics
Antonio Omuro, MD
Read More >>

December 7; 12:30PM
Pathology Grand Rounds
LMP 1094
The Evolving Landscape of Brain Metastasis
Manual Valiente, DVM, PhD
Read More >>

December 7; 2:30PM
Smilow Cancer Genetics and Prevention Program Seminar
SRC, suites 107-109
Read More >>

December 7; 5:30PM
YSPH/Global Health Concentration
Hope Memorial Building, 110
Global Health Seminar
Dena Schulman-Green
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL.

Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network.
Kwak YE, Stein SM, Lim JK.

Functional germline variants as potential co-oncogenes.
Agarwal D, Nowak C, Zhang NR, Pusztai L, Hatzis C.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Bold KW, Sussman S, O'Malley SS, Grana R, Foulds J, Fishbein H, Krishnan-Sarin S.
Addict Behav. 2017 Nov 22.

Trajectories of prostate-specific antigen after treatment for prostate cancer.
Wu Z, Aslan M, Lin H, Ko J, Radhakrishnan K, Wells CK, Uchio E, Concato J.

Submissions
Please submit your recent publication and grant announcements to:
Renee Gaudette
Director, Public Affairs and Marketing
renee.gaudette@yale.edu
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Read More >>

Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients.
Cheng JY, Li FY, Ko CJ, Colegio OR.
Read More >>

Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance.
Bagchi A, Haidar JN, Eastman SW, Vieth M, Topper M, Iacolina MD, Walker JM, Forest A, Shen Y, Novosiadly RD, Ferguson KM.
Read More >>

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Read More >>

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.
Read More >>